Agoracom Blog Home

Posts Tagged ‘penny stocks’

« Older Entries
Newer Entries »

Quantum BioPharma’s Secret Weapon: A Dual Engine of Clinical Innovation and Consumer Expansion

Posted by Brittany McNabb at 11:10 AM on Wednesday, April 16th, 2025

From clinical breakthroughs in multiple sclerosis to a fast-growing alcohol detox brand, Quantum BioPharma is bridging biotech innovation with real-world impact.

A Biopharma Platform Tackling Today’s Toughest Health Challenges

Quantum BioPharma Ltd. (NASDAQ: QNTM | CSE: QNTM) is emerging as a dynamic force in the biotechnology sector, developing solutions for two major public health issues: neurodegenerative diseases and alcohol misuse. With a diversified pipeline spanning prescription drugs and over-the-counter consumer products, the company is building an integrated portfolio capable of delivering both near-term commercial gains and long-term medical breakthroughs.

The company’s strategy is uniquely positioned at the intersection of science, innovation, and unmet need — making it one of the few small-cap biotechs advancing both FDA-bound therapeutics and consumer-ready wellness products simultaneously.

Lucid-MS: Targeting the Root Cause of Multiple Sclerosis

At the heart of Quantum’s pharmaceutical program is Lucid-MS, a patented new chemical entity showing early promise in treating multiple sclerosis (MS). Unlike conventional MS drugs that focus on managing inflammation, Lucid-MS addresses the core driver of long-term disability in MS: the breakdown of the myelin sheath — the protective layer around nerve fibers.

Following a successful Phase 1 clinical trial, the drug has been deemed safe and well-tolerated, with therapeutic blood levels observed in healthy participants. Quantum is now preparing to launch a Phase 2 trial in 2026, targeting efficacy in MS patients.

What makes Lucid-MS even more distinctive is Quantum’s collaborative study with Massachusetts General Hospital (MGH), featuring scientists from Harvard Medical School, to validate advanced PET imaging as a way to monitor demyelination in real time. This partnership elevates both the scientific credibility and clinical precision behind Lucid-MS, positioning it as a next-generation therapeutic candidate in a $27 billion global MS treatment market.

unbuzzd™: A Consumer Wellness Product with Scientific Backing

In parallel with its clinical pipeline, Quantum BioPharma is making significant inroads in the consumer wellness market through unbuzzd™, an over-the-counter alcohol detox and recovery beverage developed by its spinout, Celly Nutrition Corp. The product, a fast-acting powder stick formulated by pharmacology experts, is designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.

unbuzzd™ is already making retail waves. Backed by a double-blind, placebo-controlled clinical trial, the beverage demonstrated that it could reduce blood alcohol concentration (BAC) over 40% faster than placebo in many subjects. It’s now available via Amazon and unbuzzd.com, with retail expansion underway in the U.S., Puerto Rico, and the Caribbean through a new distribution agreement with FUSION Distribution Group.

Most recently, unbuzzd™ entered a landmark partnership with AATAC, one of the largest retail networks in the U.S., which connects the product to over 80,000 convenience store locations. This expansion gives unbuzzd™ exposure to leading chains like 7-Eleven, Circle K, Shell, and ampm — significantly scaling its retail footprint.

Multiple Value Streams, One Vision

Quantum BioPharma holds 25.71% ownership in Celly Nutrition and receives up to 7% in royalties from unbuzzd™ sales until a $250M threshold is met — and 3% in perpetuity thereafter. This structure offers upside exposure to the high-growth consumer market while maintaining strategic focus on the pharmaceutical pipeline.

With an improved cash position, enhanced operational efficiency, and momentum across both drug development and consumer wellness fronts, the company is now advancing toward key inflection points on multiple fronts.

A Biotech Story Worth Watching

With a first-in-class MS treatment advancing toward Phase 2 trials, a consumer product already on shelves and gaining market traction, and elite partnerships with global institutions like Harvard and AATAC — Quantum BioPharma stands apart in the small-cap biotech landscape.

It’s not just a company developing drugs. It’s building a platform for impact, backed by scientific validation and commercial momentum.


YOUR NEXT STEPS 

Visit $QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

Watch $QNTM Videos On AGORACOM YouTube Channel:

https://studio.youtube.com/playlist/PLfL457LW0vdK6S1r-_VHqbuWQNDV4fV-D/videos

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , , , , , ,
Posted in Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma’s Secret Weapon: A Dual Engine of Clinical Innovation and Consumer Expansion

This Small Cap Gold Company Announced 363,000 Ounces As Gold Sets Record Prices

Posted by Brittany McNabb at 4:38 PM on Tuesday, April 15th, 2025

In this interview with AGORACOM, Renforth Resources Inc. (CSE: RFR | OTCQB: RFHRF | FSE: 9RR) CEO Nicole Brewster discusses the company’s newly updated 2025 Mineral Resource Estimate for its 100%-owned Parbec Gold Deposit in Quebec — a move that significantly strengthens the company’s value proposition at a time when gold prices continue to surge. The updated estimate now totals 363,000 ounces of gold, marking a 29% increase over the previous figure and signaling growing maturity and confidence in the deposit. Notably, 265,000 ounces are now categorized as Measured and Indicated, and 87% of the total resource sits within an open pit — directly adjacent to Agnico Eagle’s Canadian Malartic Mine, one of Canada’s largest gold operations.

KEY HIGHLIGHTS: Open Pit Advantage: With mineralization starting at surface and a pit depth of 300 meters, Parbec’s economics are compelling, especially with nearby toll milling options. Strategic Fit for Agnico: The project’s location beside Canadian Malartic and proximity to multiple mills makes it a potential solution for Agnico Eagle’s “fill-the-mill” strategy — especially amid $5.6B in M&A activity in the district.

Clear Monetization Path: CEO Nicole Brewster outlines a three-path strategy: sale, joint venture, or self-development, including a plan to initiate stripping and bulk sampling this summer for potential cash flow.

A COMPELLING QUOTE FROM THE CEO “We are very happy to deliver this significant size increase to our open pit gold deposit next door to Agnico Eagle’s Canadian Malartic mine… With this MRE, 87% of the gold ounces within the resource estimate are contained within the accompanying open pit.” — Nicole Brewster, CEO

WHY INVESTORS SHOULD WATCH THIS INTERVIEW Renforth has done what many small caps struggle to achieve: increase its resource size while also upgrading confidence categories — all while controlling costs and maintaining 100% ownership in one of the world’s top-ranked mining jurisdictions. With strategic positioning next to Canada’s mining giant, viable paths to monetization, and growing relevance in a high-gold-price environment, Parbec is moving from potential to probability.

This interview isn’t just an update — it’s a real-time look into how Renforth is strategically unlocking value from its assets and evaluating serious next steps. Watch the full interview now to understand why Renforth could be a key player in Quebec’s next wave of gold development.

Tags: , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Renforth Resources | Comments Off on This Small Cap Gold Company Announced 363,000 Ounces As Gold Sets Record Prices

Kidoz Delivers Record Quarter WIth $10.7 Million In Revenue For Q4-24

Posted by Brittany McNabb at 11:04 AM on Thursday, April 10th, 2025

Kidoz Inc. (TSXV: KIDZ), the global leader in child-safe mobile advertising, just posted its strongest quarter to date—solidifying its position as the default monetization platform for digital content aimed at children under 13. 

With quarterly revenue hitting $10.7 million and a pre-tax profit of $2.9 million, the company not only returned to profitability but also showcased the strength of its privacy-first model in a rapidly evolving regulatory environment.

STRATEGIC GROWTH BACKED BY INDUSTRY GIANTS

Kidoz’s impressive growth is underpinned by key partnerships and widespread industry adoption:

  • Integrated into nearly 5,000 kid-focused apps
  • Reaches over 400 million monthly active users globally
  • Trusted by brands like Disney, LEGO, Mattel, McDonald’s, and Hasbro
  • Certified partner of Apple and Google

The company’s AI-powered contextual ad engine, which targets content—not personal behavior—is proving essential as tech platforms introduce tools to support age-appropriate experiences.

THE KID SAFE REGULATORY ADVANTAGE

As lawmakers tighten the rules around data privacy—particularly for children—Kidoz stands apart. The company is fully compliant with global standards like COPPA and GDPR-K and is already aligned with forthcoming legislation like COPPA 2.0, which will mandate age-gating and data separation for under-13 audiences.

“Unlike traditional ad networks, we don’t collect our profile user data. Our contextual AI targeting is designed from the ground up to protect kids’ privacy—and that’s become our biggest competitive advantage.”
— Jason Williams, CEO of Kidoz Inc.

LOOKING AHEAD: PROFITABILITY, SCALE & MARKET SHARE

Kidoz has committed to maintaining quarterly profitability throughout 2025. With regulators enforcing stricter data use policies and major brands seeking safe ad environments, the company is capturing a growing share of a market forecast to surpass $100 billion in digital ad spend.

With a clear regulatory tailwind, scalable technology, and a rapidly growing client base, Kidoz is not just adapting to change—it’s defining the future of child-focused digital advertising.

Tags: , , , ,
Posted in AGORACOM Via Satellite, Kidoz | Comments Off on Kidoz Delivers Record Quarter WIth $10.7 Million In Revenue For Q4-24

280,000 Ounces of Gold, Major Critical Minerals & Near $5.5B in M&A: Renforth’s Moment Is Here

Posted by Brittany McNabb at 12:48 PM on Thursday, April 3rd, 2025

Renforth Resources: Positioned for Gold and Critical Mineral Success in Quebec

In a compelling new interview with AGORACOM, Renforth Resources Inc. (CSE: RFR | OTCQB: RFHRF | FSE: 9RR) CEO Nicole Brewster laid out a clear and convincing case for why this Canadian junior exploration company is exceptionally well-positioned amid record gold prices and rising global demand for critical minerals. With flagship assets in Quebec’s world-renowned Abitibi mining district, Renforth is advancing both its 100%-owned Parbec Gold Deposit and the massive Malartic Metals Package — a combined landholding that sits in one of the richest and most active mining corridors in North America.

Strategic Location Beside Mining Giants

Renforth’s Parbec Gold Project is situated directly adjacent to Agnico Eagle’s Canadian Malartic Mine, the country’s largest open-pit gold mine. The deposit already contains 280,000 ounces of gold (101,000 oz indicated, 177,000 oz inferred), with a new NI 43-101 resource estimate expected soon. This update will include 15,000 metres of additional drilling and could significantly increase the gold resource, especially with current gold prices near C$4,500/oz.

The Parbec project benefits from exceptional infrastructure: direct road access, two hydroelectric lines crossing the property, nearby toll milling facilities, and close proximity to the Glencore-owned Horn Smelter. As Brewster puts it, “It can’t get cheaper than this — the economics of development in this region are simply unbeatable.”

Malartic Metals Package: A Critical Mineral Powerhouse

Located just north of Parbec, the 300 km² Malartic Metals Package hosts the emerging 20-kilometre-long Victoria nickel-sulphide polymetallic structure. Recent metallurgical results show that the mineralization — which includes nickel, zinc, copper, cobalt, and silver — is hosted in conventional sulphide minerals, indicating potential for standard, cost-effective processing.

Initial mineralogical analysis and TOMRA sorting tests demonstrate strong early signs of recoverability and grade optimization. Brewster also confirmed that Renforth is working with SGS to determine whether its current drilling supports a maiden resource — an important step toward unlocking value in this new discovery.

In the Midst of $5.6 Billion in M&A

Renforth is surrounded by major mining players. Agnico Eagle has spent billions acquiring and consolidating deposits across the Abitibi in recent years, including the Yamana and O3 Mining deals. Parbec sits right in the middle of this activity, offering both strategic value and expansion potential to any nearby operator looking to sustain mill throughput or grow their regional footprint.

“This is a proven gold deposit, sitting beside a mine that’s going underground and needs more ore. The strategic value is obvious,” Brewster stated.

Quebec Advantage: Cost, Policy, and Market Access

Renforth’s position in Quebec provides significant advantages beyond geology. The province is routinely ranked as a top-tier mining jurisdiction globally, and the Quebec government recently introduced new stimulus programs specifically aimed at accelerating critical mineral exploration. With access to hydroelectric power, deepwater ports, rail lines, and North America’s battery manufacturing corridor, Renforth’s assets are ideally situated to capitalize on emerging resource trends.

Conclusion: Value Waiting to Be Realized

Despite world-class assets, infrastructure, and jurisdictional advantages, Brewster noted that capital has been hard to come by for juniors — and that Renforth has instead prioritized drilling and science over promotional spending. “We’ve outlined real metals in the ground that aren’t going anywhere. What we’re building is real,” she said.

With a new gold resource estimate imminent, growing strategic relevance in the critical minerals space, and near-term catalysts ahead, Renforth Resources appears to be an underappreciated player in a district that continues to deliver major value.

For those seeking exposure to gold and critical minerals in one of the most mining-friendly regions in the world, Renforth may be one to watch.

Watch the full interview here: 

Tags: , , , ,
Posted in AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, AGORACOM Via Satellite, Renforth Resources | Comments Off on 280,000 Ounces of Gold, Major Critical Minerals & Near $5.5B in M&A: Renforth’s Moment Is Here

Canadian Biotech Quantum BioPharma Nears a Landmark Multiple Sclerosis Breakthrough

Posted by Brittany McNabb at 9:54 AM on Thursday, March 27th, 2025

New Approach Could Redefine How Multiple Sclerosis Is Treated Worldwide

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) may be on the verge of redefining treatment for multiple sclerosis (MS), a chronic neurological disorder affecting nearly 3 million people worldwide. In a compelling interview on the AGORACOM, Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at Quantum BioPharma, detailed the company’s successful completion of its Phase 1 clinical trial for Lucid-MS, a first-in-class neuroprotective drug targeting demyelination—the core driver of MS progression.

Unlike existing treatments, which primarily focus on managing the immune system and controlling inflammation, Lucid-MS takes aim at protecting and potentially repairing the myelin sheath—the protective layer around nerve cells that degenerates in MS patients. “We’re excited about the potential of Lucid-MS to protect myelin in MS patients as it represents a new direction in the treatment of this disease,” said Quantum BioPharma CEO Zeeshan Saeed.

A Novel Solution to a Persistent Problem

Most MS therapies today only address the inflammatory aspect of the disease, leaving the underlying neurodegeneration largely unaddressed. Lucid-MS changes that narrative.

  • The drug works by preventing the unraveling of the myelin sheath, a process triggered by a chemical modification known as citrullination.

  • Developed over a decade by Dr. Lakshmi Kotra and Dr. Mario Moscarello at the University of Toronto, Lucid-MS targets this key process, aiming to halt disease progression and protect nerve communication.

  • The approach has already shown success in preclinical animal models.

“Think of the myelin sheath like insulation around electrical wiring. When that’s compromised, signals can’t transmit properly,” explained Dr. Chruscinski. “Our drug preserves that insulation, maintaining neural function.”

Phase 1 Trial: Safety Confirmed, Therapeutic Potential Emerges

The recently completed Phase 1 trial focused on evaluating safety and pharmacokinetics in healthy participants. According to Dr. Chruscinski, “Lucid-MS was safe and well-tolerated, with no adverse events. We’re also pleased with the drug levels observed in blood, which we believe are therapeutic.”

This milestone is crucial for advancing to Phase 2, where the company will begin testing Lucid-MS in MS patients to assess efficacy.

What to Expect in Phase 2

The company is actively designing its Phase 2 trial with a projected start in Q1 2026, pending FDA clearance via an Investigational New Drug (IND) application in late 2025.

Key details under consideration:

  • The trial will include roughly 60 MS patients (30 receiving Lucid-MS and 30 on placebo).

  • Outcomes will be measured using MRI scans and clinical assessments to evaluate both biological and functional improvement.

  • While the exact location is yet to be confirmed, Quantum is exploring options to include Canadian sites in recognition of the drug’s Canadian origins.

Support From the Scientific Community

Feedback from global experts at major MS conferences in North America and Europe has been overwhelmingly positive. “The response has been tremendous,” said Dr. Chruscinski. “There’s a real appetite for a drug that targets neurodegeneration, which remains an unmet need in MS.”

This third-party validation underscores the broader scientific and commercial relevance of Quantum BioPharma’s work.

A Human-Centered Mission With Investor Appeal

Dr. Chruscinski also emphasized his personal motivation. “It’s exciting to be part of something that could make a real difference. I was there when the first dose was administered in our Phase 1 trial. That’s a moment I won’t forget.”

While the drug development process remains long and complex, Quantum BioPharma has achieved a significant milestone that positions the company—and Lucid-MS—at the forefront of innovation in MS treatment.

For investors, the opportunity lies in Quantum’s unique approach, successful early data, and a clearly defined path toward a potential market-shifting solution.

Conclusion: A Meaningful Milestone With a Promising Horizon

With a Phase 1 trial successfully completed and a novel therapeutic mechanism unlike anything currently on the market, Quantum BioPharma is emerging as a company to watch in the fight against multiple sclerosis. As it gears up for its Phase 2 trial and FDA engagement, the company stands at a pivotal inflection point—one that could not only deliver long-term value for investors but also reshape the future of MS care.

To hear Dr. Chruscinski explain the science, milestones, and next steps in his own words, watch the full interview here: 

Tags: , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, AGORACOM Via Satellite, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Canadian Biotech Quantum BioPharma Nears a Landmark Multiple Sclerosis Breakthrough

Canadian Small Cap Quantum BioPharma on The Verge of Multiple Sclerosis Breakthrough

Posted by Brittany McNabb at 5:01 PM on Tuesday, March 25th, 2025

KEY MILESTONES AND WHAT’S NEXT

  • Successful Phase 1 Trial: Lucid-MS has shown excellent safety with no serious side effects, paving the way for a groundbreaking treatment for MS.
  • Next Major Step: The Phase 2 trial is set for early 2026, with 60 participants.
  • FDA Submission on the Horizon: Plans to submit application to the FDA by late 2025, taking a huge step toward regulatory approval.
  • Massive Market Opportunity: With 2.9 million people worldwide affected by Multiple Sclerosis and the market projected to surpass $30 billion by 2030, Lucid-MS could potentially capture a significant share of this rapidly expanding space.

A NEW ERA IN MULTIPLE SCLEROSIS TREATMENT

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Lucid-MS is setting the stage to revolutionize MS treatment. Unlike existing therapies that only target immune system responses, Lucid-MS focuses on protecting and repairing myelin, the critical layer around nerve fibers. This novel approach has the potential to slow or even reverse disease progression—offering new hope for millions of MS sufferers.

HOW DOES IT WORK? A TOTALLY NEW APPROACH TO TREATING MS

Think of nerves like electrical wires in your body, and myelin as the protective coating around those wires. With Multiple Sclerosis, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.

Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.

WHY IS THIS IMPORTANT?

By keeping myelin intact, Lucid-MS may help slow down the progression of MS and prevent disability—something current MS drugs don’t do very well.

SCIENTIFIC BREAKTHROUGH BACKED BY INDUSTRY RECOGNITION

Lucid-MS is backed by cutting-edge research from Dr. Lakshmi Khotra’s lab at the University of Toronto, where the critical process of myelin breakdown in MS patients was discovered. The drug’s ability to address this underlying issue is a potential game-changer in neurodegenerative treatments.

It’s already gaining enthusiastic support from leading medical experts and researchers, underscoring its transformative potential.

A VISION FOR THE FUTURE

Dr. Andrzej Chruscinski, Vice President of Scientific and Clinical Affairs at Quantum BioPharma, expressed the company’s excitement about Lucid-MS’s future.

“We are on the cusp of something monumental. Lucid-MS has the potential to transform MS treatment and open doors for treating other nerve-related diseases. As we move toward Phase 2 and beyond, we’re excited to bring this innovative therapy to the patients who need it most.”

With promising clinical results, a massive market opportunity, and rising industry recognition, Quantum BioPharma is leading the charge in next-generation treatments for Multiple Sclerosis 

YOUR NEXT $QNTM STEPS

$QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopha… $QNTM Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Quantumbiopha… Connect With AGORACOM Anyway You Like AGORACOM Website: https://www.agoracom.com – The Most Trusted Source Of Small Cap Information AGORACOM YouTube: Hit That Subscribe Button Right Now For More Powerful Videos AGORACOM X: https://www.x.com/AGORACOM Verified Top 0.2% Account AGORACOM Spotify: https://open.spotify.com/show/74mVPkf… Planes, Trains, Automobiles & Walking The Dog AGORACOM

Tags: , , , , ,
Posted in AGORACOM Via Satellite, Quantum BioPharma Ltd. | Comments Off on Canadian Small Cap Quantum BioPharma on The Verge of Multiple Sclerosis Breakthrough

3 Billion Gamers, $21B Market—Why Kidoz Is Winning in Mobile AdTech

Posted by Brittany McNabb at 4:16 PM on Tuesday, March 25th, 2025

In the ever-evolving world of entertainment, gaming is no longer just a pastime—it’s the most powerful and profitable media format in the world. Surpassing film, music, and television, mobile gaming has emerged as the dominant platform for engagement, particularly among younger audiences. At the center of this transformation is Kidoz Inc. (TSXV:KIDZ), a mobile AdTech leader specializing in safe, COPPA- and GDPR-compliant digital advertising for kids and families.

As brands shift their media strategies toward platforms that guarantee attention, interaction, and safety, Kidoz is proving to be a high-performing partner in the mobile gaming ecosystem.

Gaming: The Modern Entertainment Powerhouse

Over the past decade, gaming has gone from niche to mainstream. With over 3 billion active players globally, gaming now generates more revenue than film and music combined. It’s more immersive, more social, and more accessible than ever, thanks to the ubiquity of smartphones and tablets. And while older generations still turn to traditional media, younger audiences—especially Gen Alpha and Gen Z—are spending more time gaming than on any other media platform.

This is where Kidoz thrives.

Operating within this high-growth market, Kidoz enables brands to reach young audiences where they spend their time—inside games and apps—without compromising safety or privacy. With the Kidoz Contextual Ad Network, advertisers can deliver age-appropriate, engaging content across thousands of kid-focused mobile platforms, video channels, and websites.

Record-Breaking Revenue in Q4 2024

Kidoz’s latest financial performance underscores the value of its position in the gaming-driven ad market. In Q4 2024, Kidoz reported record revenue of USD $7.44 million, marking a +23% year-over-year increase and a +225% gain over Q3 2024. The company also delivered a pre-tax profit of $2.2 million, reversing a loss from the prior quarter.

Other financial milestones include:

  • Adjusted EBITDA: $2.17 million (up from $591K in Q4 2023) 
  • Free Cash Flow: $2.34 million (vs. $37.8K in Q4 2023) 
  • Cash Reserves: $2.78 million at year-end 2024 

This performance is being driven by greater direct brand investment, increased adoption of Kidoz’s programmatic ad solutions, and strong platform optimization—making the company a standout in an increasingly crowded space.

Tapping into Gen Alpha with Contextual Precision

Gen Alpha is growing up in a world where gaming is not just entertainment—it’s culture. Mobile games are where they watch videos, socialize with friends, and engage with content. Unlike previous generations, Gen Alpha is mobile-first by default.

Kidoz’s technology ensures brands can reach this audience in a compliant, respectful, and meaningful way. The platform leverages AI-powered contextual targeting to ensure that ads are relevant, safe, and delivered in the right environment—without relying on personal data or intrusive tracking methods.

This makes Kidoz a go-to solution for brands like LEGO, Mattel, Disney, and Kraft, all of whom have launched campaigns through the Kidoz network to engage young users effectively and ethically.

The Future of AdTech Is Kid-Safe, High-Performance, and Global

Looking ahead to 2025 and beyond, Kidoz is expanding its global footprint through direct brand relationships and strategic event participation. With industry-leading tools like the Kidoz Publisher SDK and Kidoz COPPA Shield, the company continues to raise the standard for what’s possible in mobile advertising.

With the kids’ digital advertising market projected to surpass $21 billion by 2031, and regulatory changes like COPPA 2.0 expected to expand the total addressable market, Kidoz is not only riding the wave—it’s helping to shape it.

As gaming cements itself as the entertainment format of the future, Kidoz is uniquely positioned to be the platform that connects the world’s most trusted brands with the next generation of digital consumers—securely, effectively, and at scale.

Source: https://www.kidoz.net/blog/gaming-reigns-supreme-the-entertainment-industrys-powerhouse

YOUR NEXT STEPS 

 

Visit $KIDZ HUB On AGORACOM:http:// https://agoracom.com/ir/Kidoz

Visit $KIDZ 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Kidoz/profile

Visit $KIDZ Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Kidoz/forums/discussion

Watch $KIDZ Videos On AGORACOM YouTube Channel:

https://www.youtube.com/feed/library

DISCLAIMER AND DISCLOSURE  

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

 

If you have any questions, please direct them to [email protected] 

 

For our full website disclaimer, please visithttp://  https://agoracom.com/terms-and-conditions

Tags: , , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, Kidoz | Comments Off on 3 Billion Gamers, $21B Market—Why Kidoz Is Winning in Mobile AdTech

Quantum BioPharma Successfully Completes First Human Trial for New Multiple Sclerosis Drug 

Posted by Brittany McNabb at 1:18 PM on Monday, March 24th, 2025

Key Takeaway for Investors:
Quantum BioPharma (NASDAQ: QNTM) has successfully completed its Phase 1 clinical trial for Lucid-21-302 (Lucid-MS), an experimental drug for multiple sclerosis (MS). The drug was found to be safe and well-tolerated, paving the way for the next phase of clinical testing.

What Happened?
The company conducted a Phase 1 trial to test the safety of Lucid-MS in healthy volunteers. The study followed strict protocols, including a final review by a Safety Review Committee, which confirmed there were no safety concerns or serious side effects.

Why This Matters:
Lucid-MS is a first-of-its-kind drug designed to protect the myelin sheath around nerve fibers, which is damaged in MS patients. Unlike existing MS treatments, which primarily focus on the immune system, Lucid-MS directly works to stabilize myelin, potentially slowing disease progression.

Next Steps:
With safety confirmed, Quantum BioPharma now plans to move forward with a Phase 2 trial, which will test Lucid-MS in MS patients to evaluate its effectiveness in treating the disease.

CEO Statement:
Zeeshan Saeed, CEO of Quantum BioPharma, emphasized the significance of this milestone, stating that the company is now closer to making a breakthrough treatment for MS patients a reality.

Investor Outlook:
The successful completion of Phase 1 is a major step toward potential drug approval and commercialization. Investors should keep an eye on upcoming Phase 2 trial developments, as positive results could significantly increase the drug’s market potential.

What Does Lucid-21-302 Do? (In Simple Terms)

Lucid-21-302 (Lucid-MS) is a new experimental drug designed to protect nerve fibers in people with multiple sclerosis (MS).

How Does It Work?
Think of nerves like electrical wires in your body, and myelin as the protective coating around those wires. In MS, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.

Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.

Why Is This Important?
By keeping myelin intact, Lucid-MS may help slow down the progression of MS and prevent disability—something current MS drugs don’t do very well.
If future trials confirm its effectiveness, it could be a game-changer for people living with MS.

Source: https://agoracom.com/ir/Quantumbiopharma/forums/discussion/topics/808536-Quantum-BioPharma-Advances-Multiple-Sclerosis-Drug-with-Successful-Phase-1-Trial-Completion-A-Milestone-in-MS-Treatment-Development/messages/2432086

 

Tags: , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Successfully Completes First Human Trial for New Multiple Sclerosis Drug 

VanadiumCorp is About to Supercharge Clean Energy—You Won’t Believe the Numbers!

Posted by Brittany McNabb at 5:09 PM on Thursday, March 13th, 2025

A Leader in Vanadium Electrolyte Production

VanadiumCorp Resource Inc. (TSX-V: VRB) is emerging as a leader in the rapidly growing sector of long-duration energy storage, specifically through the production of high-quality vanadium electrolyte for Vanadium Flow Batteries (VFBs). These innovative batteries are crucial to the decarbonization of electrical grids worldwide, offering a reliable and sustainable energy storage solution for renewable energy systems.

With its roots deeply embedded in the Canadian mining industry, VanadiumCorp is strategically positioned in Québec, one of the world’s most favorable mining jurisdictions. The company’s commitment to responsible and environmentally sustainable practices aligns with global energy trends and the push for cleaner, greener solutions in energy storage.

Key Milestones Driving Growth

VanadiumCorp’s journey has been marked by several significant milestones, each reinforcing its potential as a key player in the energy storage and critical metals sectors.

  1. Production of Vanadium Electrolyte
    In Q1 2024, VanadiumCorp’s manufacturing plant in Val-des-Sources, Québec, officially began producing high-purity vanadium electrolyte. This marks a pivotal moment for the company, as it secures its place in the growing VFB market, catering to original equipment manufacturers (OEMs) worldwide. With the capacity to produce 300,000 liters annually, the plant is already positioned to generate initial revenues, setting the stage for further expansion.
  2. Expanding Manufacturing Capacity
    The success of the Val-des-Sources plant has laid the foundation for the company’s ambitious expansion plans. VanadiumCorp is already scoping a second plant in Sherbrooke, Québec, set to produce 4 million liters per year. Expected to come online in Q1 2025, this new facility will significantly enhance the company’s ability to meet the growing demand for VFBs, with a long-term goal of producing 26 million liters of electrolyte annually by 2028.
  3. Lac Doré: A Strategic Mineral Deposit
    VanadiumCorp’s flagship asset, the Lac Doré vanadium-titanium-iron deposit, located near Chibougamau, Québec, promises a stable, long-term supply of vanadium for electrolyte production. The company is actively advancing metallurgical testing and environmental permitting to move the deposit closer to full-scale production. Once operational, the Lac Doré mine could produce 10,000 tonnes of V2O5 per year, providing the foundation for the company’s electrolyte manufacturing needs and positioning VanadiumCorp as a key supplier in the global market.

The Growing Demand for Vanadium Flow Batteries

As renewable energy sources like solar and wind continue to gain momentum, the need for long-duration energy storage solutions has never been more urgent. Vanadium Flow Batteries are uniquely suited to meet this demand, offering the ability to store large amounts of energy over extended periods, unlike traditional lithium-ion batteries. With a lifespan of decades and minimal degradation over time, VFBs represent a compelling solution for stabilizing electrical grids, particularly for projects reliant on variable renewable energy sources.

The global VFB market is expanding rapidly, driven by the need for efficient and durable energy storage solutions. VanadiumCorp’s strategic focus on both electrolyte manufacturing and mineral resource development positions the company to play a vital role in this burgeoning industry.

A Sustainable and Strategic Approach

VanadiumCorp’s success is built on its commitment to environmental sustainability. Its manufacturing facilities operate using clean, hydroelectric power, ensuring a minimal carbon footprint. Additionally, the company’s efforts to incorporate environmentally friendly practices into every aspect of its operations—from mining to production—align with global goals for reducing greenhouse gas emissions and supporting the transition to a cleaner energy future.

As the demand for energy storage continues to soar, VanadiumCorp’s early involvement in both the vanadium supply chain and electrolyte production makes it an exciting player in the energy storage and critical metals space. With a strong track record of achieving milestones, expanding capacity, and securing strategic assets, VanadiumCorp is positioned for continued growth and success in the years to come.

YOUR NEXT STEPS 

Visit $VRB HUB On AGORACOM :http:// https://agoracom.com/ir/VanadiumcorpResource

Visit $VRB 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/VanadiumcorpResource/profile

Visit $VRB Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/VanadiumcorpResource/forums/discussion

DISCLAIMER AND DISCLOSURE  

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

 

If you have any questions, please direct them to [email protected] 

For our full website disclaimer, please visit http://  https://agoracom.com/terms-and-conditions

 

Tags: , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, Vanadium, Vanadiumcorp | Comments Off on VanadiumCorp is About to Supercharge Clean Energy—You Won’t Believe the Numbers!

PyroGenesis Partners with GE Vernova to Drive Industrial Electrification and Sustainability

Posted by Brittany McNabb at 2:14 PM on Thursday, March 13th, 2025

PyroGenesis Inc. (TSX: PYR), a global leader in advanced plasma technology, has entered into a strategic collaboration with GE Vernova, the energy arm of General Electric, to drive the transition toward cleaner, more energy-efficient industrial processes. This move marks a significant step in the company’s mission to replace fossil fuel combustion with all-electric plasma torches, particularly in energy-intensive industries such as aluminum, steel, cement, and alumina production. The collaboration is set to accelerate the development of solutions aimed at reducing the environmental impact of high-temperature processes.

A Groundbreaking Partnership for Industrial Electrification

The collaboration, formalized through a Memorandum of Understanding (MOU), brings together PyroGenesis’ innovative plasma technology with GE Vernova’s extensive expertise in power conversion and electrical infrastructure. The two companies aim to develop solutions that can replace traditional fossil fuel-powered technologies with cleaner, all-electric systems. This shift is critical as industries such as aluminum, steel, cement, and quicklime production account for a significant portion of global greenhouse gas emissions due to their reliance on fossil fuels for high-temperature processing.

The MOU outlines a multi-phase approach that begins with studying the implementation of PyroGenesis’ plasma torches for use in large industrial facilities like iron ore pellet plants and primary aluminum smelter casthouses. With the combined expertise of both companies, the initiative aims to deliver multi-megawatt solutions capable of meeting the high energy demands of these industries while significantly reducing their carbon footprint.

Key Benefits of the PyroGenesis-GE Vernova Collaboration

  • Transition to Clean Energy: The partnership is a pivotal step in electrifying industrial sectors that traditionally rely on fossil fuels. By replacing fuel combustion with plasma torches, these sectors can dramatically reduce their CO2 emissions, contributing to broader sustainability goals.
  • Energy Efficiency: PyroGenesis’ plasma torches have already shown the ability to reduce energy consumption compared to traditional methods. The technology is expected to improve overall operational efficiency, resulting in lower costs and faster production times, thus benefiting industries with high energy demands.
  • Scalability and Versatility: The collaboration specifically targets multi-megawatt systems, suitable for industries like aluminum, steel, and cement that require large-scale, high-temperature solutions. The ability to scale these technologies to meet growing industrial demands positions PyroGenesis and GE Vernova as leaders in industrial electrification.

The Strategic Impact on Global Heavy Industry

The global move toward sustainability has intensified, with industries under pressure to reduce emissions and embrace cleaner, more efficient technologies. For companies like PyroGenesis, the demand for energy-efficient solutions is creating vast growth opportunities. Through this partnership with GE Vernova, PyroGenesis is expanding its reach into critical industrial sectors that are increasingly focusing on decarbonization.

Not only does the collaboration provide an opportunity to advance sustainable practices within heavy industries, but it also allows PyroGenesis to expand its market footprint. GE Vernova, a trusted name in energy, brings extensive experience in power conversion and industrial electrification, ensuring the project’s success and the broader implementation of electric-powered plasma systems across major industries.

Expert Insights on the Collaboration

Ed Torres, Business Leader at GE Vernova, emphasized the significance of the partnership: “This collaboration is a key step in supporting industries as they transition to a cleaner, more sustainable future. By leveraging PyroGenesis’ plasma technology and our expertise in electrical infrastructure, we aim to revolutionize high-temperature processes across multiple industries.”

  1. Peter Pascali, President and CEO of PyroGenesis, expressed excitement about the partnership’s potential: “This collaboration with GE Vernova is an exciting next step in our mission to electrify emissions-intensive industries. With their industry-leading technology and our proven plasma torches, we can create energy-efficient solutions that will change the future of industrial processes.”

A Sustainable Future Ahead

The PyroGenesis-GE Vernova collaboration represents a critical step toward the electrification of heavy industries, aligning with global efforts to reduce carbon emissions and transition toward a more sustainable future. As industries continue to adopt cleaner energy solutions, PyroGenesis stands at the forefront of this transformation, offering innovative plasma technology that promises to revolutionize industrial manufacturing.

Source: https://agoracom.com/ir/PyroGenesisCanada/forums/discussion/topics/808875-PyroGenesis-Partners-with-GE-Vernova-to-Drive-Industrial-Electrification/messages/2432957

YOUR NEXT STEPS 

Visit $PYR HUB On AGORACOM:http:// https://agoracom.com/ir/PyroGenesisCanada

Visit $PYR 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/PyroGenesisCanada/profile

Visit $PYR Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/PyroGenesisCanada/forums/discussion

Watch $PYR Videos On AGORACOM YouTube Channel:

https://studio.youtube.com/video/PKBOqIcMQlg/edit

DISCLAIMER AND DISCLOSURE  

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

 

If you have any questions, please direct them to [email protected] 

For our full website disclaimer, please visit http://  https://agoracom.com/terms-and-conditions

Tags: , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, PyroGenesis Canada Inc. | Comments Off on PyroGenesis Partners with GE Vernova to Drive Industrial Electrification and Sustainability

« Older Entries
Newer Entries »